Show simple item record

dc.contributor.authorPiccolo, Enza
dc.contributor.authorTinari, Nicola
dc.contributor.authorD’Addario, Domenica
dc.contributor.authorRossi, Cosmo
dc.contributor.authorIacobelli, Valentina
dc.contributor.authorLa Sorda, Rossana
dc.contributor.authorLattanzio, Rossano
dc.contributor.authorD’Egidio, Maurizia
dc.contributor.authorDi Risio, Annalisa
dc.contributor.authorPiantelli, Mauro
dc.contributor.authorNatali, Pier G
dc.contributor.authorIacobelli, Stefano
dc.date.accessioned2015-09-01T17:31:08Z
dc.date.available2015-09-01T17:31:08Z
dc.date.issued2015-07-30
dc.identifier.citationJournal of Translational Medicine. 2015 Jul 30;13(1):248
dc.identifier.urihttp://dx.doi.org/10.1186/s12967-015-0606-x
dc.identifier.urihttp://hdl.handle.net/10724/31809
dc.description.abstractAbstract Background A previous report has shown that LGALS3BP (also known as 90K or Mac-2 BP) has antitumor activity in colorectal cancer (CRC) via suppression of Wnt signalling with a novel mechanism of ISGylation-dependent ubiquitination of β-catenin. The role of LGALS3BP in CRC prognosis was investigated. Methods The role of LGALS3BP on CRC progression and clinical prognosis was analyzed by combining cell cultures, in vitro assays, and immunohistochemistry. Results Silencing of LGALS3BP in HCT-116 human colon cancer cells resulted in enhanced β-catenin expression that was reversed by addition of human recombinant LGALS3BP. Moreover, intra-tumor delivery of LGALS3BP reduced tumor growth of xenografts originating from LGALS3BP-silenced HCT-116 cells. Finally, in a series of 196 CRC patients, LGALS3BP expression in tumor tissue associated with clinical outcome. Patients with high LGALS3BP expression had lower risk of relapse and a longer overall survival time than those with low LGALS3BP expression. Multivariate analyses confirmed LGALS3BP expression status as the only independent prognostic factor of survival. Conclusions These results provide evidence that low expression of LGALS3BP participates in malignant progression of CRC and implicates poor prognosis, highlighting its augmentation as a potential therapeutic approach.
dc.titlePrognostic relevance of LGALS3BP in human colorectal carcinoma
dc.typeJournal Article
dc.date.updated2015-07-29T18:32:38Z
dc.language.rfc3066en
dc.rights.holderPiccolo et al.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record